Is the price fair?
What TECH's price assumes
Bio-Techne trades at 105× earnings against 32.4× for the median Biotechnology name, more expensive than its own group.
105
Trailing P/E · Biotechnology median 32.4 · 3.24× the median: the market pays up for this one
- Price / sales
- 6.78
Price / sales · as of 2026-Q1
- Free cash flow yield
- 3.0%
Free cash flow yield · Biotechnology median 2.5%
- Growth the price implies
- +13%
Growth the price implies · The price pays for +13% free cash flow growth a year for a decade; the business has delivered +5.0% a year over the last three.
Details›
- Price / book2026-Q1
- 3.94
- Healthcare median P/E362 names
- 31.5
- Biotechnology median P/E158 names
- 32.4
- Free cash flow, trailing twelve months
- $270M
- Market capitalisation
- $9.07B
- 3-year revenue growth
- +2.5%
- 3-year free cash flow growth
- +5.0%
| Method | Per share |
|---|---|
| What its own history would imply | not meaningful, 104× today against a 17.4× median |
| 52-week range | $43.22 – $72.51 |
| Today | $72.39 |
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.